Arimoclomol is an orally available, CNS-penetrant coinducer of heat shock proteins (HSPs), notably HSP70, that exhibits in vivo efficay in disease models of diabetes, Gaucher disease (GD), sporadic inclusion body myositis (sIBM), and neurological disorders, including amyotrophic lateral sclerosis (ALS) and Niemann-Pick disease type C1 (NPC1). Note: arimoclomol maleate and citrate salt forms are known as BRX-220 and BRX-345, respectively.
Orally available, CNS-penetrant coinducer of heat shock proteins (HSPs), notably HSP70 (HSP72), with in vivo ALS, GD, NPC1, and sIBM therapeutic efficacy.
Nontoxic heat shock protein (HSP) inducer compounds open up promising therapeutic possibilities by activating one of the natural and highly conserved defense mechanisms of the organism. In the present experiments, we examined the effects of a HSP coinducer drug-candidate, BRX-220
Heat shock proteins (hsps) are induced in a variety of cells following periods of stress, where they promote cell survival. In this study, we examined the effect of upregulating hsp expression by treatment with BRX-220, a co-inducer of hsps, on
Journal of neurochemistry, 107(2), 339-350 (2008-08-05)
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by motoneuron degeneration, resulting in muscle paralysis and death, typically within 1-5 years of diagnosis. Although the pathogenesis of ALS remains unclear, there is evidence for the involvement of proteasome
Sporadic inclusion body myositis (sIBM) is the commonest severe myopathy in patients more than 50 years of age. Previous therapeutic trials have targeted the inflammatory features of sIBM but all have failed. Because protein dyshomeostasis may also play a role
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition in which motoneurons of the spinal cord and motor cortex die, resulting in progressive paralysis. This condition has no cure and results in eventual death, usually within 1-5 years of diagnosis.
